Laird Norton Wetherby Wealth Management LLC Sells 196 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Laird Norton Wetherby Wealth Management LLC reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,920 shares of the medical equipment provider’s stock after selling 196 shares during the quarter. Laird Norton Wetherby Wealth Management LLC’s holdings in Zimmer Biomet were worth $414,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its holdings in shares of Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock valued at $369,469,000 after purchasing an additional 2,796,372 shares during the last quarter. Norges Bank acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at about $216,223,000. Dodge & Cox grew its stake in shares of Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock valued at $2,019,480,000 after acquiring an additional 2,044,645 shares in the last quarter. Sound Shore Management Inc. CT acquired a new stake in Zimmer Biomet during the fourth quarter worth about $81,447,000. Finally, FMR LLC grew its stake in Zimmer Biomet by 91.6% during the fourth quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider’s stock worth $151,897,000 after buying an additional 687,675 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a report on Tuesday, May 6th. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley dropped their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Tuesday, May 6th. Finally, Raymond James lowered their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $113.45.

Zimmer Biomet Price Performance

ZBH opened at $96.68 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a market capitalization of $19.13 billion, a price-to-earnings ratio of 21.73, a P/E/G ratio of 1.95 and a beta of 0.78. The firm’s fifty day moving average price is $103.62 and its two-hundred day moving average price is $105.92. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $122.17.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.94 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.